Business
GenSight Biologics Reports Cash Position as of September 30, 2025
PARIS, October 07, 2025--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2025.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0012905089839146878617ed24f784fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pnw.5JD_TtU6nVONdiYNJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0012905089839146878617ed24f784fd","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position amounted to €0.6 million as of September 30, 2025","length":63,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successful closing of fundraising worth nearly EUR3.7 million on October 1, 2025","length":80,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position amounted to €3.6 million as of October 1, 2025","length":60,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":203,"olType":false},{"type":"text","content":"PARIS, October 07, 2025--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2025.","length":359,"tagName":"p"},{"type":"text","content":"Cash Position and Outlook","length":25,"tagName":"p"},{"type":"text","content":"GenSight Biologics' cash and cash equivalents totalled €0.6 million as of September 30, 2025, compared to €0.3 million as of June 30, 2025.","length":143,"tagName":"p"},{"type":"text","content":"On October 1, 2025, the company received the net proceeds from the fundraising completed on September 26, 2025, totaling €3.0 million, net of the repayment of €0.7 million principal on the convertible bonds held by Heights Capital. As of October 1, 2025, GenSight Biologics' cash and cash equivalents totaled €3.6 million.","length":326,"tagName":"p"},{"type":"text","content":"The company has sufficient net working capital to meet its obligations only until the end of the fourth quarter of 2025. However, the cash runway cou...